Spisulosine

Spisulosine is a lipid of Sphingolipids (SP) class. Spisulosine is associated with abnormalities such as Infection, Renal impairment and Lesion of brain. The involved functions are known as Gene Expression, Cell Cycle, Drug Kinetics, Signal Transduction and Cell Cycle Arrest. Spisulosine often locates in Body tissue, Microfilaments, Skin, Stress Fibers and Tissue specimen.

Cross Reference

Introduction

To understand associated biological information of Spisulosine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Spisulosine?

Spisulosine is suspected in Infection, Renal impairment, Lesion of brain and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

No disease MeSH terms mapped to the current reference collection.

PubChem Associated disorders and diseases

What pathways are associated with Spisulosine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Spisulosine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Spisulosine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Spisulosine?

There are no associated biomedical information in the current reference collection.

What genes are associated with Spisulosine?

There are no associated biomedical information in the current reference collection.

What common seen animal models are associated with Spisulosine?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Spisulosine

Download all related citations
Per page 10 20 50 | Total 35
Authors Title Published Journal PubMed Link
Fabišíková M et al. Total synthesis and the anticancer activity of (+)-spisulosine. 2016 Carbohydr. Res. pmid:27693911
Steiner R et al. Elucidating the chemical structure of native 1-deoxysphingosine. 2016 J. Lipid Res. pmid:27165858
Duan J and Merrill AH 1-Deoxysphingolipids Encountered Exogenously and Made de Novo: Dangerous Mysteries inside an Enigma. 2015 J. Biol. Chem. pmid:25947379
Esaki K et al. L-Serine Deficiency Elicits Intracellular Accumulation of Cytotoxic Deoxysphingolipids and Lipid Body Formation. 2015 J. Biol. Chem. pmid:25903138
Wei N et al. Altered sphingoid base profiles in type 1 compared to type 2 diabetes. 2014 Lipids Health Dis pmid:25305670
Kowluru A Deoxysphingolipids: β-cell, beware of these new kids on the block. 2014 Diabetes pmid:24651803
Zuellig RA et al. Deoxysphingolipids, novel biomarkers for type 2 diabetes, are cytotoxic for insulin-producing cells. 2014 Diabetes pmid:24379346
Calder ED et al. Preparation of anti-vicinal amino alcohols: asymmetric synthesis of D-erythro-sphinganine, (+)-spisulosine, and D-ribo-phytosphingosine. 2013 J. Org. Chem. pmid:23795558
Abad JL et al. Straightforward access to spisulosine and 4,5-dehydrospisulosine stereoisomers: probes for profiling ceramide synthase activities in intact cells. 2013 J. Org. Chem. pmid:23679346
Byun HS et al. Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. 2013 Medchemcomm pmid:24396570
Xu K et al. A highly anti-selective asymmetric Henry reaction catalyzed by a chiral copper complex: applications to the syntheses of (+)-spisulosine and a pyrroloisoquinoline derivative. 2012 Chemistry pmid:22907874
Massard C et al. Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors. 2012 Invest New Drugs pmid:22215532
Vilar E et al. A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. 2012 Invest New Drugs pmid:20820909
Chen BS et al. Diastereoselective synthesis and bioactivity of long-chain anti-2-amino-3-alkanols. 2011 Eur J Med Chem pmid:21955681
Garofalo K et al. Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. 2011 J. Clin. Invest. pmid:22045570
Scherer SS The debut of a rational treatment for an inherited neuropathy? 2011 J. Clin. Invest. pmid:22045569
Rotthier A et al. Characterization of two mutations in the SPTLC1 subunit of serine palmitoyltransferase associated with hereditary sensory and autonomic neuropathy type I. 2011 Hum. Mutat. pmid:21618344
Merrill AH Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. 2011 Chem. Rev. pmid:21942574
Schöffski P et al. Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies. 2011 Cancer Chemother. Pharmacol. pmid:21465314
Malik G et al. Aziridines from intramolecular alkene aziridination of sulfamates: reactivity toward carbon nucleophiles. application to the synthesis of spisulosine and its fluoro analogue. 2011 J. Org. Chem. pmid:21812488